1BCZiYR

More documents

Recommendations

Info

EASL PREMIUM SPONSORS 2015 EASL thanks its Premium Sponsors AbbVie, Bristol-Myers Squibb and Gilead for their generous contribution and support of the association’s activities with unrestricted educational grants. THE INTERNATIONAL LIVER CONGRESS 2015 SPONSORS EASL acknowledges the following companies’ dedication and generous support for The International Liver Congress 2015 PLATINUM SPONSORS AbbVie Bristol-Myers Squibb Gilead Janssen Pharmaceutical Companies of Johnson & Johnson GOLD SPONSOR MSD SILVER SPONSORS Bayer HealthCare Norgine Shire Pharmaceuticals Synageva BioPharma Corp. OTHER SPONSORS PRO.MED.CS Praha a.s. Intercept Pharmaceuticals LIST OF EXHIBITORS AbbVie ALFA WASSERMANN S.p.A. Baxter Healthcare Bayer HealthCare BIOPREDICTIVE FIBROTEST Biotest AG Bristol-Myers Squibb Cepheid Cleveland Clinic Abu Dhabi Dr. Falk Pharma GmbH Echosens Epistem Ltd Fresenius Medical Care Fujirebio Europe NV Galmed Pharmaceuticals Ltd. GE Healthcare Gilead Gore & Associates IC-HEP - The International Coalition of Hepatology Education Providers Intercept Pharmaceuticals International New York Times INVENTIVA USA Italy Switzerland USA France Germany USA France UAE Germany France UK Germany Belgium Israel Germany UK Germany USA USA France France 18 The International Liver Congress 2015 • ILC Programme
Janssen Pharmaceutical Companies of Johnson & Johnson MEDA Merz Pharmaceuticals GmbH MSD Norgine OraSure Technologies, Inc. OWL Metabolomics Perspectum Diagnostics Ltd PHILIPS PhoenixBio PRO.MED.CS Praha a.s. RESONANCE HEALTH ANALYSIS SERVICES LTD Sanofi (Beijing) Pharmaceuticals Co., Ltd Sequana Medical AG Shire Pharmaceuticals Sirtex Medical Europe GmbH Steinhäuser Verlag SuperSonic Imagine Synageva BioPharma Corp. Virology Education Vital Therapies, Inc. Belgium Sweden Germany USA UK USA Spain UK The Netherlands Japan Czech Republic Australia China Switzerland Switzerland Germany Germany France USA The Netherlands USA Wako Chemicals GmbH Wiley Wisepress Bookshop Wuxi Hisky Medical Technologies Co.,ltd NON-GOVERNMENTAL ORGANISATIONS (NGOS) & ASSOCIATIONS AASLD ALEH APASL CHB EASL ELPA PHC UEG WHA Germany UK UK China American Association for the Study of Liver Diseases Latin-America Association for the Study of the Liver Asian Pacific Association for the Study of the Liver Cochrane Hepato-Biliary European Association for the Study of the Liver European Liver Patients Association ISVHLD 2015 / Deutsche Leberstiftung Liver Foundation, West Bengal Paris Hepatitis Conference United European Gastroenterology University of Liverpool World Hepatitis Alliance Vienna, Austria • April 22–26, 2015 19
Page 1 and 2: PROGRAMME VIENNA, AUSTRIA APRIL 22-
Page 3 and 4: VIENNA, AUSTRIA APRIL 22-26, 2015 O
Page 5 and 6: A HISTORY OF INNOVATION A SUSTAINED
Page 7 and 8: CONTENTS EASL Governing Board 8 Wel
Page 9 and 10: EASL EDUCATIONAL COUNCILLORS EU POL
Page 11 and 12: WELCOME MESSAGE Dear Colleague, Wel
Page 13 and 14: LET US KNOW ON THE EASL INSPIRATION
Page 15 and 16: WELCOME FROM THE HONORARY PRESIDENT
Page 17: McPherson Stuart, United Kingdom Mo
Page 21 and 22: EASL AWARDS FRIDAY, APRIL 24, 2015
Page 23 and 24: LIVER DISEASE IN RESOURCE-LIMITED S
Page 25 and 26: WS = Joint Workshop cont. = continu
Page 27 and 28: WEDNESDAY, APRIL 22, 2015 Strauss 1
Page 29 and 30: THURSDAY, APRIL 23, 2015 Strauss 3
Page 31 and 32: FRIDAY, APRIL 24, 2015 Early Mornin
Page 33 and 34: SATURDAY, APRIL 25, 2015 Strauss 3
Page 35 and 36: SUNDAY, APRIL 25, 2015 Stolz 2 Meta
Page 37 and 38: SCIENTIFIC PROGRAMME WEDNESDAY APRI
Page 39 and 40: Joint Workshop: EASL-ICA Strauss 1
Page 41 and 42: Post-Graduate Course: Liver Transpl
Page 43 and 44: Joint Workshop: EASL-Public Health
Page 45 and 46: Joint Workshop: EASL-MSF-Prolifica-
Page 47 and 48: Joint Workshop: EASL-Virtual Liver
Page 49 and 50: Joint Workshop: EASL-International
Page 51 and 52: Post Graduate Course - Metabolic Li
Page 53 and 54: Basic Science Seminar - Liver Tumou
Page 55 and 56: Nurses and Associates Forum Lehar 3
Page 57 and 58: SCIENTIFIC PROGRAMME THURSDAY APRIL
Page 59 and 60: Post Graduate Course - Metabolic Li
Page 61 and 62: Basic Science Seminar - Liver Tumou
Page 63 and 64: Fellowship and Registry Grant Prese
Page 65 and 66: Parallel Session: Viral Hepatitis C
Page 67 and 68: Parallel Session: General Viral Hep
Page 69 and 70:
Parallel Session: Non-invasive mark
Page 71 and 72:
Parallel Session: Alcohol and DILI
Page 73 and 74:
Parallel Session: Liver immunology
Page 75 and 76:
SCIENTIFIC PROGRAMME FRIDAY APRIL 2
Page 77 and 78:
Clinical Use of HBsAg quantificatio
Page 79 and 80:
General Session 2 & Award Ceremony
Page 81 and 82:
Grand Rounds: Liver transplantation
Page 83 and 84:
Joint workshop: EASL-EFSUMB Lecture
Page 85 and 86:
Translational Workshop - Liver mito
Page 87 and 88:
Parallel Session: Viral Hepatitis C
Page 89 and 90:
Parallel Session: Cirrhosis and Com
Page 91 and 92:
Parallel Session: Fatty Liver Disea
Page 93 and 94:
Parallel Session: Liver Tumours: Cl
Page 95 and 96:
SCIENTIFIC PROGRAMME SATURDAY APRIL
Page 97 and 98:
General Session 3 & Award Ceremony
Page 99 and 100:
Parallel Session: EU and Public Hea
Page 101 and 102:
Parallel Session: Liver Inflammatio
Page 103 and 104:
Parallel Session: Liver Transplanta
Page 105 and 106:
Joint Workshop: EASL-EFSUMB Lecture
Page 107 and 108:
Clinical Symposium - Bacterial infe
Page 109 and 110:
Joint Workshop: EASL - JSH Stolz 2
Page 111 and 112:
SCIENTIFIC PROGRAMME SUNDAY APRIL 2
Page 113 and 114:
Study design in gut microbiome asse
Page 115 and 116:
30 Years of Journal of Hepatology:
Page 117 and 118:
Clinical Symposium - Value-Based Me
Page 119 and 120:
ePOSTERS THURSDAY, APRIL 23, 2015 F
Page 121 and 122:
P0007 P0008 HEPATIC T-CELLS DERIVED
Page 123 and 124:
YI P0020 YI P0021 YI P0022 ROLE OF
Page 125 and 126:
P0033 P0034 P0035 PROSPECTIVE EVALU
Page 127 and 128:
P0046 P0047 RESPONSE TO LOCO-ABLATI
Page 129 and 130:
YI P0058 YI P0059 SOFOSBUVIR-BASED
Page 131 and 132:
YI P0068 YI P0069 ALCOHOLIC ETIOLOG
Page 133 and 134:
YI P0079 YI P0080 NUCLEOS(T)IDE ANA
Page 135 and 136:
YI P1301 YI P1302 YI P1303 A NOVEL
Page 137 and 138:
P0088 P0089 P0090 FERMENTED MILK CO
Page 139 and 140:
TOP 10% YI P0102 YI P0103 YI P0104
Page 141 and 142:
Cirrhosis and its Complications: Cl
Page 143 and 144:
P0129 P0130 P0131 PORTAL HYPERTENSI
Page 145 and 146:
P0140 P0141 P0142 FRAILTY ASSESSMEN
Page 147 and 148:
P0151 P0152 COVERT HEPATIC ENCEPHAL
Page 149 and 150:
P0162 P0163 P0164 CRITICAL FLICKER
Page 151 and 152:
YI P0174 YI P0175 SOLUBLE CD163 (SC
Page 153 and 154:
YI P0185 YI P0186 ACUTE-ON-CHRONIC
Page 155 and 156:
Cirrhosis and its Complications: Bl
Page 157 and 158:
YI P0210 YI P0211 COMBINED PARTIAL
Page 159 and 160:
Liver Tumours: Experimental P0220 P
Page 161 and 162:
P0232 P0233 P0234 REDUCED TRANSCRIP
Page 163 and 164:
P0245 P0246 P0247 THE IL-6/SIL6R AN
Page 165 and 166:
TOP 10% YI P0259 YI P0260 TRANSENDO
Page 167 and 168:
YI P0271 YI P0272 YI P0273 EFFECTS
Page 169 and 170:
YI P0283 YI P0284 YI P0285 ADENOSIN
Page 171 and 172:
YI P0295 YI P0296 YI P0297 CD4+CD25
Page 173 and 174:
YI P0309 YI P0310 GENE EXPRESSION P
Page 175 and 176:
P0321 YI P0322 YI P0323 INCREASED A
Page 177 and 178:
P0330 P0331 COST-EFFECTIVENESS ANAL
Page 179 and 180:
P0341 P0342 P0343 DECREASING MORTAL
Page 181 and 182:
P0355 P0356 THE EVALUATION OF AN AU
Page 183 and 184:
YI P0367 YI P0368 YI P0369 SARCOPEN
Page 185 and 186:
P0376 P0377 STRATIFICATION OF HEPAT
Page 187 and 188:
YI P0387 YI P0388 YI P0389 IDENTIFI
Page 189 and 190:
P0400 P0401 YI P0402 MICRORNA SIGNA
Page 191 and 192:
YI P0414 YI P0415 YI P0416 CONSTITU
Page 193 and 194:
P0426 P0427 INHIBITION OF MONOACYLG
Page 195 and 196:
YI P0439 YI P0440 YI P0441 YI P0442
Page 197 and 198:
Liver Immunology Including Viral He
Page 199 and 200:
P0465 P0466 P0467 PERSISTENT INTRAH
Page 201 and 202:
TOP 10% YI P0476 TOP 10% YI P0477 T
Page 203 and 204:
YI P0488 YI P0489 DISSECTING THE CO
Page 205 and 206:
YI P0501 YI P0502 YI P0503 REDUCED
Page 207 and 208:
Non-Invasive Markers of Liver Fibro
Page 209 and 210:
YI P0518 YI P0519 ARTERIAL PRESSURE
Page 211 and 212:
Viral Hepatitis: Hepatitis B & D -
Page 213 and 214:
P0543 P0544 P0545 COMPARATIVE EVALU
Page 215 and 216:
YI P0556 YI P0557 YI P0558 ANTIVIRA
Page 217 and 218:
Viral Hepatitis: Hepatitis A, B, D
Page 219 and 220:
P0581 P0582 PREDICTION OF HBSAG SER
Page 221 and 222:
P0592 P0593 P0594 A CROSS-SECTIONAL
Page 223 and 224:
TOP 10% YI P0604 TOP 10% YI P0605 Y
Page 225 and 226:
YI P0614 KEY HBSAG MUTATIONS SIGNIF
Page 227 and 228:
YI P0625 YI P0626 A HYPER-GLYCOSYLA
Page 229 and 230:
Viral Hepatitis: Hepatitis B & D -
Page 231 and 232:
P0643 P0644 SERUM HBV RNA IS AN EAR
Page 233 and 234:
P0654 P0655 LONG-TERM SUSTAINED SUP
Page 235 and 236:
YI P0665 YI P0666 HBV VARIANTS PRES
Page 237 and 238:
P0676 P0677 CLEARANCE OF PERSISTENT
Page 239 and 240:
P0688 YI P0689 PRECLINICAL CHARACTE
Page 241 and 242:
YI P0699 YI P0700 YI P0701 EPIGENET
Page 243 and 244:
Viral Hepatitis: Hepatitis C - Clin
Page 245 and 246:
P0720 P0721 IMPROVEMENT OF ADVANCED
Page 247 and 248:
P0732 P0733 P0734 IMPACT OF OLD SCH
Page 249 and 250:
P0745 P0746 EQ-5D UTILITY INDEX IN
Page 251 and 252:
YI P0759 YI P0760 YI P0761 HEPATITI
Page 253 and 254:
P0770 P0771 EFFECT OF HEPATITIS C A
Page 255 and 256:
P0781 P0782 HIGH SVR RATES DESPITE
Page 257 and 258:
P0789 P0790 EFFECTIVENESS, SAFETY A
Page 259 and 260:
P0800 P0801 P0802 EFFECTIVENESS AND
Page 261 and 262:
P0810 P0811 SOFOSBUVIR AND DACLATAS
Page 263 and 264:
P0821 P0822 ARE EXTENDED DURATIONS
Page 265 and 266:
P0834 P0835 SIGNIFICANT DRUG-DRUG I
Page 267 and 268:
P0846 P0847 EVALUATION OF ADHERENCE
Page 269 and 270:
P0857 P0858 98% SVR12 IN KOREAN AND
Page 271 and 272:
P0869 P0870 EARLY VERSUS DELAYED US
Page 273 and 274:
YI P0879 YI P0880 EXAMINING THE CLI
Page 275 and 276:
Viral Hepatitis: Hepatitis C - Clin
Page 277 and 278:
P0899 P0900 PRECLINICAL PROFILE OF
Page 279 and 280:
P0910 YI P0911 NO EVIDENCE OF PHARM
Page 281 and 282:
Fatty Liver Disease: Experimental P
Page 283 and 284:
P0932 P0933 P0934 TREATMENT WITH NG
Page 285 and 286:
YI P0944 YI P0945 YI P0946 MODULATI
Page 287 and 288:
YI P0957 YI P0958 YI P0959 VITAMIN
Page 289 and 290:
YI P0970 YI P0971 FAT-LADDEN MACROP
Page 291 and 292:
Fatty Liver Disease: Clinical P0978
Page 293 and 294:
P0990 P0991 P0992 NON-ALCOHOLIC STE
Page 295 and 296:
P1002 P1003 THE HISTOLOGICAL SEVERI
Page 297 and 298:
P1016 P1017 P1018 FACTORS ASSOCIATE
Page 299 and 300:
P1028 P1029 P1030 IMPAIRED AEROBIC
Page 301 and 302:
P1040 TOP 10% YI P1041 SHORT-TERM L
Page 303 and 304:
YI P1050 YI P1051 ASSOCIATION OF FA
Page 305 and 306:
YI P1061 YI P1062 YI P1063 THE MACR
Page 307 and 308:
YI P1074 YI P1075 YI P1076 YI P1077
Page 309 and 310:
P1089 P1091 P1092 CELLULAR SENESCEN
Page 311 and 312:
P1103 P1104 P1105 PORTAL HYPERTENSI
Page 313 and 314:
YI P1117 YI P1118 YI P1119 HISTOLOG
Page 315 and 316:
YI P1132 YI P1133 YI P1134 REGULATI
Page 317 and 318:
P1143 P1144 P1145 THYROID HORMONE R
Page 319 and 320:
P1154 P1155 P1156 P1158 PRE-TREATME
Page 321 and 322:
P1169 P1170 OUTCOME INDICATORS IN P
Page 323 and 324:
YI P1180 YI P1181 IDENTIFICATION OF
Page 325 and 326:
YI P1189 YI P1190 DECREASED SERUM T
Page 327 and 328:
YI P1200 YI P1201 THE EFFECT OF AZA
Page 329 and 330:
Genetic and Pediatric Liver Disease
Page 331 and 332:
P1224 P1225 P1226 NEXT-GENERATION S
Page 333 and 334:
YI P1238 YI P1239 YI P1240 INTERMED
Page 335 and 336:
P1249 P1250 ALCOHOLIC LIVER DISEASE
Page 337 and 338:
P1262 P1263 P1264 AN ACCURATE SCORE
Page 339 and 340:
P1273 P1274 ACUTE PORTAL VEIN THROM
Page 341 and 342:
YI P1288 BUDD CHIARI SYNDROM (BCS)
Page 343 and 344:
P1313 P1314 WTX101-201: PHASE 2 STU
Page 345 and 346:
P1323 YI P1324 YI P1325 A STUDY TO
Page 347 and 348:
P1334 A MULTICENTRE, RANDOMISED, OP
Page 349 and 350:
YI P1344 P1345 DETERMINING THE HEPA
Page 351 and 352:
LATE BREAKER ePOSTERS
Page 353 and 354:
LP05 LP06 DACLATASVIR PLUS SOFOSBUV
Page 355 and 356:
LP14 LP15 A PHASE 3, RANDOMISED, OP
Page 357 and 358:
LP24 LP25 SAFETY, EFFICACY AND IMPA
Page 359 and 360:
LP34 LP35 EX VIVO LIVER RESECTION A
Page 361 and 362:
LP44 LP45 PHAGOCYTOSIS: HOW THE BEG
Page 364 and 365:
EVERYTHING YOU NEED FOR THE INTERNA
Page 366 and 367:
TECHNICAL INFORMATION TECHNICAL INF
Page 368 and 369:
EVENTS 2015 LIVER DISEASE IN RESOUR
Page 370 and 371:
GENERAL INFORMATION GENERAL INFORMA
Page 372 and 373:
GENERAL INFORMATION SPEAKERS' READY
Page 374 and 375:
EVENTS 2016 T-CELL RESPONSES IN VIR
Page 376 and 377:
SPONSORS’ SYMPOSIA WEDNESDAY, APR
Page 378 and 379:
SPONSORS’ SYMPOSIA THURSDAY, APRI
Page 380 and 381:
SPONSORS’ SYMPOSIA THURSDAY, APRI
Page 382 and 383:
SPONSORS’ SYMPOSIA FRIDAY, APRIL
Page 384 and 385:
SPONSORS’ SYMPOSIA SATURDAY, APRI
Page 386 and 387:
VENUE FLOOR PLAN INDUSTRY INFORMATI
Page 388 and 389:
EXHIBITORS LIST INDUSTRY INFORMATIO
Page 390 and 391:
COMPANY PROFILES AbbVie 230 1 North
Page 392 and 393:
Bristol-Myers Squibb 260 206, Provi
Page 394 and 395:
Fresenius Medical Care 1, Else-Kroe
Page 396 and 397:
IC-HEP - The International Coalitio
Page 398 and 399:
Merz Pharmaceuticals GmbH 100, Ecke
Page 400 and 401:
PhoenixBio 1-3-4, Kagamiyama 739004
Page 402 and 403:
Steinhäuser Verlag 410 E SuperSoni
Page 404 and 405:
Wisepress Bookshop 25 High Path Lon
Page 406 and 407:
Cochrane Hepato-Biliary Rigshospita
Page 408 and 409:
University of Liverpool 70 Pembroke
Page 410 and 411:
NOTES 410 The International Liver C
Page 412 and 413:
NOTES 412 The International Liver C
Page 416 and 417:
OLYSIO ® - At the Core of HCV Cure
Page 418:
Visit BOOTH 230 ALL NEW, ALL-ORAL,
show all

1BCZiYR

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?